SCHEMBL6774688

SCHEMBL6774688

NC(=O)C#Cc1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.41
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
GPR183 P32249 1/20 0.39
ACACB O00763 1/20 0.39
TSHR P16473 2/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
HTT P42858 1/20 0.39
NLRP3 Q96P20 1/20 0.39
GSK3B P49841 2/20 0.39
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALOX15 P16050 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KCNH2 Q12809 1/20 0.37
CHRM1 P11229 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guanidine SCHEMBL2281423 0.80 LMNA (0.39) NPC1PTGDR2GPR183ACACBTSHR
SCHEMBL2636129 0.80 TSHR (0.44) PTGDR2CES2CES1GPR183ACACB
SCHEMBL8443823 0.80 KCNH2 (0.42) PTGDR2CES2CES1GPR183ACACB
SCHEMBL6574954 0.80 APP (0.52) NPC1LMNAMAPTHTTALOX15
SCHEMBL10794117 0.78 TSHR (0.43) PTGDR2CES2CES1GPR183ACACB
SCHEMBL21066942 0.78 GPR183 (0.40) CES2CES1GPR183ACACBLMNA
SCHEMBL6776577 0.78 APP (0.49) NPC1CES2CES1GPR183ALDH1A1
SCHEMBL4487823 0.78 ACACB (0.46) PTGDR2CES2CES1GPR183ACACB
SCHEMBL6781061 0.78 VCP (0.52) CES2CES1ACACBLMNAGSK3B
SCHEMBL3696839 0.77 NPSR1 (0.55) NPC1MAPTHTTCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023274246-A1 AMIDE COMPOUND AND USE THEREOF 成都分迪药业有限公司 2023-01-05 WO disclosed
US-20190192524-A1 Modulators of Caspase-6 UNIVERSITY OF HAMBURG (DE) 2019-06-27 US disclosed
EP-3129027-A1 MODULATORS OF CASPASE-6 University of British Columbia (CA) 2017-02-15 EP disclosed
WO-2016020732-A1 MODULATORS OF CASPASE-6 THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2016-02-11 WO disclosed
US-6767906-B2 INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. NOVARTIS AG (CH) 2004-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192524-A1 Modulators of Caspase-6 CASP6, CASP10, CASP2 NPC1 1977/4885PTGDR2 3574/4885CES2 2833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.